戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 en radiographic progression and radiographic nonprogression.
2  contributes to the maintenance of long-term nonprogression.
3 5+ MuLV), while others demonstrate long-term nonprogression.
4 ally responsible for in vitro resistance and nonprogression.
5  HIV-1 variants is associated with long term nonprogression.
6 37 (87%) patients displaying nonlinearity or nonprogression.
7 V(1), DLco, and emphysema progression versus nonprogression.
8 of HIV-2-infected patients exhibit long-term nonprogression.
9 atients demonstrated at least one episode of nonprogression after an episode of progression, that is,
10 ppear to play a dominant mechanistic role in nonprogression among HIV-infected individuals.
11  benchmark datasets-one representing "likely nonprogression" and the other representing "likely progr
12 alence of nonlinear trajectories, periods of nonprogression, and of rapid progression.
13  region are described in series of long-term nonprogression cases.
14  in 28 joints [DAS28] <2.6) and radiographic nonprogression (change in the modified Sharp/van der Hei
15 of Resistance to Immunodeficiency Virus AIDS nonprogression cohort and compared them with those of co
16                     The rate of radiographic nonprogression (defined as a total modified Sharp/van de
17 ], stable disease [SD] > 16 weeks, or CA-125 nonprogression &gt; 16 weeks), which was the primary end po
18 rts revealed that individuals with long-term nonprogression have significantly lower anti-CD4bd antib
19 eviewers correctly identified progression or nonprogression in 76.0% of the slide pairs.
20 be found associated with slow progression or nonprogression in a majority of such cases.
21  the host defense mechanisms responsible for nonprogression in CCR5 heterozygotes are unknown.
22                    The mechanisms underlying nonprogression in HIV-1-infected children are not well u
23 e definition selected describes radiographic nonprogression in individual patients as an increase of
24 neous viral control, reduced viral load, and nonprogression in infected subjects and protection in va
25  the determination of the state of long-term nonprogression in some HIV-1- infected individuals, it i
26  serum antibody responses and that long-term nonprogression is not associated with homologous neutral
27             Factors accounting for long-term nonprogression may include infection with an attenuated
28 oportions of subjects achieving radiographic nonprogression (n = 360) were 89/99, 74/99, 59/79, and 5
29 T NJC predicted emphysema progression versus nonprogression (odds ratio, 2.24; 95% CI: 1.37, 3.50; P
30 nsfer constant (K(i)) at day 2 predicted for nonprogression of disease.
31 ed by (1) patients without CAV at 1 year and nonprogression over time (56.3%), (2) patients without C
32 or HLA-DQB1*06, previously associated with a nonprogression phenotype.
33 geting of epitopes associated with long-term nonprogression) predicted to correlate with protection f
34  immune response may contribute to long-term nonprogression, though studies are confounded by heterog
35 TAFTIPSI (TI8) are associated with long-term nonprogression to AIDS.
36 ivo trait associated with self-tolerance and nonprogression to diabetes.
37  with Agathobacter and Ruminococcus 2, while nonprogression was consistently associated with Prevotel
38 igher percentage of CD45RA(+)CD4(+) T cells, nonprogression was not associated with higher thymic out
39 progression occurred, a subsequent period of nonprogression was uncommon.
40 ction, the specificity for detecting "likely nonprogression" was 94% and the sensitivity for detectin
41                                   Periods of nonprogression were also common, present in 110 (70%) pa
42                               Progression or nonprogression were determined at 2 years (tier 1) and 4
43                                  Episodes of nonprogression were less common (P < 0.001) in patients